A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 15.6% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancertherapyulndialysisradiation
  Phrases that lowered it: participantsmalephysicalmassindex
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 19 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 60 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Primary purpose: supportive care (lowers risk) · Design
• Sponsor's past trials: 224 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: double (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) NCT03311555 · started 2018 · scored riskier than 99% of active trials completed
• A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide NCT05526248 · started 2022 · scored riskier than 53% of active trials completed
• Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy NCT02203695 · started 2015 · scored riskier than 95% of active trials completed
• A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer NCT01637402 · started 2013 · scored riskier than 67% of active trials completed
• Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy NCT02903368 · started 2016 · scored riskier than 73% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.